BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 33418374)

  • 1. Ketamine's rapid antisuicidal effects are not attenuated by Buprenorphine.
    Hosanagar A; Schmale A; LeBlanc A
    J Affect Disord; 2021 Mar; 282():252-254. PubMed ID: 33418374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism.
    Williams NR; Heifets BD; Bentzley BS; Blasey C; Sudheimer KD; Hawkins J; Lyons DM; Schatzberg AF
    Mol Psychiatry; 2019 Dec; 24(12):1779-1786. PubMed ID: 31467392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suicide Has Many Faces, So Does Ketamine: a Narrative Review on Ketamine's Antisuicidal Actions.
    Lengvenyte A; Olié E; Courtet P
    Curr Psychiatry Rep; 2019 Dec; 21(12):132. PubMed ID: 31797066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent Use of Buprenorphine, Methadone, or Naltrexone Does Not Inhibit Ketamine's Antidepressant Activity.
    Marton T; Barnes DE; Wallace A; Woolley JD
    Biol Psychiatry; 2019 Jun; 85(12):e75-e76. PubMed ID: 30926131
    [No Abstract]   [Full Text] [Related]  

  • 6. Ketamine Use in Child and Adolescent Psychiatry: Emerging Data in Treatment-Resistant Depression, Insights from Adults, and Future Directions.
    Ryan K; Hosanagar A
    Curr Psychiatry Rep; 2023 Aug; 25(8):337-344. PubMed ID: 37389787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suicidality in treatment resistant depression: perspective for ketamine use.
    Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wilkowska A; Słupski J; Włodarczyk A; Górska N; Szarmach J; Szałach ŁP; Wiglusz MS; Krysta K; Cubała WJ
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):258-260. PubMed ID: 31488737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression.
    Averill LA; Averill CL; Gueorguieva R; Fouda S; Sherif M; Ahn KH; Ranganathan M; D'Souza DC; Southwick SM; Sanacora G; Duman RS; Krystal JH; Abdallah CG
    J Affect Disord; 2022 Apr; 303():91-97. PubMed ID: 35101523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD).
    Chen MH; Lin WC; Wu HJ; Cheng CM; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Su TP
    J Affect Disord; 2019 May; 251():162-169. PubMed ID: 30925267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketamine: The final frontier or another depressing end?
    Sial OK; Parise EM; Parise LF; Gnecco T; Bolaños-Guzmán CA
    Behav Brain Res; 2020 Apr; 383():112508. PubMed ID: 32017978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.
    Price RB; Iosifescu DV; Murrough JW; Chang LC; Al Jurdi RK; Iqbal SZ; Soleimani L; Charney DS; Foulkes AL; Mathew SJ
    Depress Anxiety; 2014 Apr; 31(4):335-43. PubMed ID: 24668760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study.
    Chen MH; Cheng CM; Gueorguieva R; Lin WC; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Krystal JH; Su TP
    Neuropsychopharmacology; 2019 Nov; 44(12):2112-2118. PubMed ID: 31421635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
    Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
    Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
    Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
    Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine use for pain and suicidal ideation in severely suicidal patients.
    Gibbs HM; Price D; Delgado PL; Clothier JL; Cáceda R
    Int J Psychiatry Med; 2020 Nov; 55(6):387-396. PubMed ID: 32216493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
    Zarate CA; Brutsche NE; Ibrahim L; Franco-Chaves J; Diazgranados N; Cravchik A; Selter J; Marquardt CA; Liberty V; Luckenbaugh DA
    Biol Psychiatry; 2012 Jun; 71(11):939-46. PubMed ID: 22297150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion.
    Lin WC; Su TP; Li CT; Wu HJ; Tsai SJ; Bai YM; Tu PC; Chen MH
    J Psychopharmacol; 2023 Aug; 37(8):795-801. PubMed ID: 37332247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidepressant and antisuicidal effects of ketamine on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression: A double-blind, placebo-controlled, randomized, longitudinal resting fMRI study.
    Chen MH; Lin WC; Tu PC; Li CT; Bai YM; Tsai SJ; Su TP
    J Affect Disord; 2019 Dec; 259():15-20. PubMed ID: 31437695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.